The Motley Fool··Eric VolkmanCorcept Therapeutics Surges 9% on FDA Approval of Cancer Drug Lifyorli
Corcept Therapeutics stock surged 9% following FDA approval of cancer drug Lifyorli. An analyst upgraded the stock to hold amid concerns about existing Korlym franchise performance.
CORTFDA approvalbiotech